

JC17 Rec'd PCT/PTO 23 APR 2001 T

Docket:

NEB-165-PUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Raleigh, et al..

EXAMINER:

SERIAL NO .:

09/701,626

GROUP:

FILED:

December 1, 2000

FOR:

Restriction Enzyme Gene Discovery Method

The Honorable Commissioner of Patents And Trademarks Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, §1.97 and §1.98, Applicants wish to bring the following references, References AA-AL, BA, CA-CL, CN-CZ, DA-DZ and EA-EE cited on the attached PTO-1449 Form to the attention of the Examiner.

REMARKS

No representation is made that more pertinent, although presently unknown art does not exist. It is anticipated that the Examiner will conduct a thorough search of the prior art, and will carefully consider each of the said documents cited herein.

It is respectfully requested that each of the documents shown on the PTO-1449 Form be made of record in this Application.

ATENT & Raleigh, et al.

U.S.Š.N.:

09/701,626

Filed:

December 1, 2000

Page

Early examination and allowance of the present Application is respectfully requested.

Respectfully submitted,

NEW ENGLAND BIOLABS, INC.

Gregory D. Williams (Reg. No. 30901) 32 Tozer Road Beverly, MA 01915

(978) 927-5054; Ext: 292

I hereby certify that this INFORMATION DISCLOSURE STATEMENT, PTO-1449 FORM and REFERENCES AA-AL, BA, CA-CL, CN-CZ, DA-DZ ands EA-EE are being deposited with the United States Postal Service as first class mail in an envelope addressed to: ASSISTANT COMMISSIONER FOR PATENTS, Washington, D.C. 20231 on this 18th day of